Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

New phase III trials evaluate switch to doravirine/islatravir in HIV patients on other regimens

March 3, 2020

ViiV Healthcare presents new antivirals for HIV infection

Feb. 27, 2020

GlaxoSmithKline and ViiV Healthcare present compounds for HIV infection

Feb. 25, 2020

New HDAC inhibitors disclosed by Merck & Co.

Feb. 20, 2020

TaiMed studies TMB-365 in first-in-human trial for HIV-1

Feb. 12, 2020

Newly identified HIV broadly neutralizing antibody is hard to escape

Feb. 11, 2020

HVTN702 HIV vaccine study stopped early due to non-efficacy

Feb. 4, 2020

Reservoir dogs don't hunt

Feb. 4, 2020

Researchers achieve the reversal of HIV and SIV latency in vivo

Jan. 27, 2020

DFH Therapeutics and HHS describe betulinic acid derivatives for HIV infection

Jan. 22, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...